In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on BioMarin, with a price target of $120. The company’s shares opened today at $100.
According to TipRanks.com, Moussatos is a 2-star analyst with an average return of 0.2% and a 42.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on BioMarin is a Strong Buy with an average price target of $117.33, which is a 17.3% upside from current levels. In a report issued on September 6, Piper Jaffray also maintained a Buy rating on the stock with a $120 price target.
Editas Medicine Inc (EDIT)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Editas Medicine Inc. The company’s shares opened today at $32.26.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.5% and a 56.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Editas Medicine Inc with a $45.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.